Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics Regains Rights for Tamoxifen Treatment Response Test from Roche

NEW YORK, Jan. 30 (GenomeWeb News) - Epigenomics said today that its has regained the full rights to a tamoxifen treatment response test from Roche Diagnostics.

 

Epigenomics, which is focused on developing tests based on DNA methylation, said that it will now handle the full development of the test itself.

 

The tissue-based test is designed to predict the probability of disease recurrence in breast cancer patients, and was part of a multi-product collaboration with Roche Diagnostics, Epigenomics said.

 

The companies are still collaborating on the development of three screening products for colon, prostate and breast cancers.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.